Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 10/20 | 0.34 |
| ▸ | HCRTR2 | O43614 | 10/20 | 0.34 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.34 |
| ▸ | PRCP | P42785 | 5/20 | 0.34 |
| ▸ | PTGES | O14684 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL889333 | 0.96 | CHEK2 (0.34) | HCRTR1HCRTR2CHEK2PRCPPTGES | |
| SCHEMBL10120199 | 0.91 | PRCP (0.40) | HCRTR1HCRTR2CHEK2PRCPPTGES | |
| SCHEMBL889354 | 0.89 | PRCP (0.34) | HCRTR1HCRTR2CHEK2PRCPPTGES | |
| SCHEMBL889377 | 0.88 | PRCP (0.33) | HCRTR1HCRTR2CHEK2PRCPPTGES | |
| SCHEMBL890203 | 0.88 | PRCP (0.36) | HCRTR1HCRTR2CHEK2PRCPPTGES | |
| SCHEMBL889381 | 0.88 | PRCP (0.36) | HCRTR1HCRTR2CHEK2PRCPPTGES | |
| SCHEMBL10121429 | 0.86 | HCRTR1 (0.39) | HCRTR1HCRTR2CHEK2PRCP | |
| SCHEMBL889363 | 0.86 | PREP (0.35) | HCRTR1HCRTR2CHEK2PRCPPTGES | |
| SCHEMBL22361400 | 0.86 | HCRTR1 (0.40) | HCRTR1HCRTR2CHEK2PRCP | |
| SCHEMBL10121556 | 0.86 | PRCP (0.42) | HCRTR1HCRTR2CHEK2PRCP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9156818-B2 | Hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2015-10-13 | — | — | US | disclosed |
| US-9156818-B2 | Hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2015-10-13 | — | — | US | disclosed |
| US-20110064698-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110064698-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, EIF2AK2, SLC10A1 | HCRTR1 3277/4885HCRTR2 4149/4885CHEK2 4338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.